Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the first-in-human Phase I study of the novel CELMoD agent mezigdomide (CC-92480), a cereblon E3 ligase modulator, for relapsed/refractory multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
